Funding agencies: This work was supported by NIH grant K23 MH067894 (to D.W.).
Article first published online: 24 MAY 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 11, pages 2051–2057, September 2011
How to Cite
Morley, J. F., Weintraub, D., Mamikonyan, E., Moberg, P. J., Siderowf, A. D. and Duda, J. E. (2011), Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. Mov. Disord., 26: 2051–2057. doi: 10.1002/mds.23792
Relevant conflicts of interest/financial disclosures: Dr. Morley has received travel funding from Teva Pharmaceutical Industries Ltd. Dr. Weintraub has served on a scientific advisory board for Boehringer Ingelheim; serves on the editorial board of Movement Disorders; has received speaker honoraria from Boehringer Ingelheim, ACADIA Pharmaceuticals, Novartis, Osmotica Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi-aventis, and Pfizer Inc; and has received/receives research support from Avid Radiopharmaceuticals, Inc., Boehringer Ingelheim, National Institutes of Health (NIMH K23 MH067894 [PI], NINDS P50 NS053488-01 [coinvestigator], NIA RO1AG031348 [site PI], and NINDS R01NS065087 [coinvestigator]), and from the Michael J. Fox Foundation for Parkinson's Research. Ms. Mamikonyan reports no disclosures. Dr. Siderowf serves on a scientific advisory board for, and has received speaker honoraria from, Teva Pharmaceutical Industries Ltd.; serves as a consultant for Supernus Pharmaceuticals, Inc.; and receives research support from Avid Radiopharmaceuticals, Inc., the NIH (NINDS U10 NS044451-023 [Site PI], NINDS P50 NS053488-01 [cocore leader and project leader], NINDS R43NS0636071 [site PI], and NINDS R01NS065087 [coinvestigator]), and from the Institute for Neurodegenerative Disorders. Dr. Duda serves on a grant review panel for the Michael J. Fox Foundation for Parkinson's Research; receives research support from the U.S. Department of Veterans Affairs (Merit Award [PI]), the Michael J. Fox Foundation, and the Samueli Institute; and holds stock in C.R. Bard, Inc., Celgene, Clarient, Inc., and Johnson & Johnson. Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 19 SEP 2011
- Article first published online: 24 MAY 2011
- Manuscript Accepted: 18 APR 2011
- Manuscript Revised: 11 APR 2011
- Manuscript Received: 8 DEC 2010
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.